Zogenix Inc (ZGNX) 2.71 $ZGNX
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why Zogenix Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a biopharmaceutical company...
Why Zogenix (ZGNX) Stock is Up Today
at The Street - Wed Apr 16, 11:33AM CDT
Zogenix (ZGNX) rose Wednesday after a U.S. District Court stopped Massachusetts from implementing a ban on the pharmaceutical company's prescription painkiller Zohydro. The court ruled federal law superseded the state's ban, which Massachusetts...
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Prevented Access to Zohydro(TM) ER
PR Newswire - Tue Apr 15, 3:00PM CDT
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro(TM) ER on Constitutional grounds. This order will become effective on April 22, 2014.
Let's Get the Facts Straight About Zohydro(TM) ER--and the Important Patient Need It Fills
PR Newswire - Fri Apr 11, 7:30AM CDT
Rampant misinformation about Zohydro(TM) ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence.
New Painkiller Banned: Massachusetts Fallout
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Apr 10, 4:00AM CDT
Zoegenics ' Zohydro has been contentious since well before its approval by the FDA. After all, the FDA's advisory committee voted overwhelmingly against approval -- and the FDA then approved the drug despite that vote! The drug is indicated for the...
Alcoa and Facebook are big market movers
AP - Wed Apr 09, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Technical Data on Top Gainers -- Research on Palo Alto Networks, Zogenix, Seabridge Gold, and KT Corp.
PR Newswire - Wed Apr 09, 9:43AM CDT
The US markets saw a positive sentiment on Tuesday, April 08, 2014, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 advanced 0.38%, to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrial and Telecommunication Services sectors. A number of stocks saw large movements, including Palo Alto Networks Inc. (NYSE: PANW), Zogenix Inc. (NASDAQ: ZGNX), Seabridge Gold Inc. (NYSE: SA) and KT Corp. (NYSE: KT). Free technical research on PANW, ZGNX, SA and KT can be downloaded upon signing up at:
Zogenix Update on Legal Action
PR Newswire - Tue Apr 08, 8:04PM CDT
Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for Monday, April 14, 2014.
Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro(TM) ER
PR Newswire - Mon Apr 07, 3:08PM CDT
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick, which prohibits the prescribing and dispensing of the Company's prescription pain product that was approved by the U.S. Food and Drug Administration (FDA). Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, is the first and only extended-release hydrocodone without acetaminophen for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
FDA, HHS Reaffirm Support for Chronic Pain Patients Amid Zohydro ER Debate
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Health and Human Services (HHS) Secretary Kathleen Sebelius, and U.S. Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg, called for a balanced approach in the fight against prescription drug abuse and preserving the protection of the needs and rights of patients suffering from severe chronic pain. It was an impressive showcase of a unified front and a call for all stakeholders to help at every level.
Zogenix Statement: Let's Get the Facts Straight About Zohydro ER
PR Newswire - Wed Apr 02, 8:46PM CDT
We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro(TM) ER that has been demonstrated to be false.
Zogenix Reports Granting of Inducement Awards
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive employees.
Zogenix Statement: Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain
PR Newswire - Thu Mar 27, 9:00PM CDT
We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication.
Zogenix Appoints James Breitmeyer to Its Board of Directors
GlobeNewswire - Wed Mar 26, 7:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, announced today that James B. Breitmeyer, M.D., Ph.D., has been appointed as a new member of the Company's Board of Directors.
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Zogenix (ZGNX) Is Down Today
at The Street - Fri Mar 14, 10:42AM CDT
Zogenix continues to drop today after Sen. Joe Manchin (D-W.Va.) sumitted a bill to have the company's hydrocodone painkiller Zohydro removed from the market.
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why Zogenix Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a biopharmaceutical company...
Why Zogenix (ZGNX) Stock is Up Today
at The Street - Wed Apr 16, 11:33AM CDT
Zogenix (ZGNX) rose Wednesday after a U.S. District Court stopped Massachusetts from implementing a ban on the pharmaceutical company's prescription painkiller Zohydro. The court ruled federal law superseded the state's ban, which Massachusetts...
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Prevented Access to Zohydro(TM) ER
PR Newswire - Tue Apr 15, 3:00PM CDT
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro(TM) ER on Constitutional grounds. This order will become effective on April 22, 2014.
Let's Get the Facts Straight About Zohydro(TM) ER--and the Important Patient Need It Fills
PR Newswire - Fri Apr 11, 7:30AM CDT
Rampant misinformation about Zohydro(TM) ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence.
New Painkiller Banned: Massachusetts Fallout
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Apr 10, 4:00AM CDT
Zoegenics ' Zohydro has been contentious since well before its approval by the FDA. After all, the FDA's advisory committee voted overwhelmingly against approval -- and the FDA then approved the drug despite that vote! The drug is indicated for the...
Alcoa and Facebook are big market movers
AP - Wed Apr 09, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Technical Data on Top Gainers -- Research on Palo Alto Networks, Zogenix, Seabridge Gold, and KT Corp.
PR Newswire - Wed Apr 09, 9:43AM CDT
The US markets saw a positive sentiment on Tuesday, April 08, 2014, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 advanced 0.38%, to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrial and Telecommunication Services sectors. A number of stocks saw large movements, including Palo Alto Networks Inc. (NYSE: PANW), Zogenix Inc. (NASDAQ: ZGNX), Seabridge Gold Inc. (NYSE: SA) and KT Corp. (NYSE: KT). Free technical research on PANW, ZGNX, SA and KT can be downloaded upon signing up at:
Zogenix Update on Legal Action
PR Newswire - Tue Apr 08, 8:04PM CDT
Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for Monday, April 14, 2014.
Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro(TM) ER
PR Newswire - Mon Apr 07, 3:08PM CDT
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick, which prohibits the prescribing and dispensing of the Company's prescription pain product that was approved by the U.S. Food and Drug Administration (FDA). Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, is the first and only extended-release hydrocodone without acetaminophen for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
FDA, HHS Reaffirm Support for Chronic Pain Patients Amid Zohydro ER Debate
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Health and Human Services (HHS) Secretary Kathleen Sebelius, and U.S. Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg, called for a balanced approach in the fight against prescription drug abuse and preserving the protection of the needs and rights of patients suffering from severe chronic pain. It was an impressive showcase of a unified front and a call for all stakeholders to help at every level.
Zogenix Statement: Let's Get the Facts Straight About Zohydro ER
PR Newswire - Wed Apr 02, 8:46PM CDT
We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro(TM) ER that has been demonstrated to be false.
Zogenix Reports Granting of Inducement Awards
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive employees.
Zogenix Statement: Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain
PR Newswire - Thu Mar 27, 9:00PM CDT
We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication.
Zogenix Appoints James Breitmeyer to Its Board of Directors
GlobeNewswire - Wed Mar 26, 7:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, announced today that James B. Breitmeyer, M.D., Ph.D., has been appointed as a new member of the Company's Board of Directors.
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Zogenix (ZGNX) Is Down Today
at The Street - Fri Mar 14, 10:42AM CDT
Zogenix continues to drop today after Sen. Joe Manchin (D-W.Va.) sumitted a bill to have the company's hydrocodone painkiller Zohydro removed from the market.
